SCHEMBL13767016

SCHEMBL13767016

O=C(NC1C2CCCC1CCC2)c1cnn(CCC2CCNCC2)c1OCC1CCCCC1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLAT P00750 2/20 0.36
HSD11B1 P28845 6/20 0.36
LMNA P02545 1/20 0.34
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
NR3C1 P04150 1/20 0.34
IRAK4 Q9NWZ3 1/20 0.33
IDH1 O75874 3/20 0.33
GRM5 P41594 1/20 0.33
MAP4K3 Q8IVH8 1/20 0.33
TP53 P04637 1/20 0.32
GUCY1B2 O75343 1/20 0.31
GUCY1A2 P33402 1/20 0.31
GUCY1A1 Q02108 1/20 0.31
GUCY1B1 Q02153 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13767015 0.93 HSD11B1 (0.40) HSD11B1LMNA
SCHEMBL13766746 0.83 HSD11B1 (0.40) HSD11B1LMNA
SCHEMBL13766992 0.83 HSD11B1 (0.39) PLATHSD11B1LMNA
SCHEMBL13766973 0.81 HSD11B1 (0.39) HSD11B1LMNA
SCHEMBL13766982 0.81 HSD11B1 (0.47) HSD11B1LMNAIDH1GRM5
SCHEMBL13766944 0.81 HSD11B1 (0.40) HSD11B1LMNA
SCHEMBL17226597 0.81 CPB2 (0.44)
SCHEMBL13767038 0.80 HSD11B1 (0.38) PLATHSD11B1LMNA
SCHEMBL13772137 0.80 JAK2 (0.34) PLATLMNAPIM1PIM3PIM2
SCHEMBL13767041 0.80 HSD11B1 (0.39) HSD11B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY HSD17B1, HSD11B1, HSD3B1 PLAT 4594/4885HSD11B1 2/4885LMNA 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.